Evidence map›Paper›PMID 39752860›Full record

ReviewJournal of food and drug analysis2024

Updates on the conversion of nanosuspensions to solid oral dosage forms.

Anastasia Tsiaxerli, Elisavet Vardaka, Christos Moutroupidis, Kevin M G Taylor, Kyriakos Kachrimanis, Maria Malamatari

Abstract readReview
In one paragraph

Review in Journal of food and drug analysis, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Tableting of nanoparticle-based formulations for oral delivery: Enhancing biopharmaceutical performance.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Anastasia TsiaxerliDepartment of Pharmaceutical Technology, Faculty of Pharmacy, Aristotle University of Thessaloniki, 54124, Thessaloniki, Greece.
Elisavet VardakaDepartment of Pharmaceutical Technology, Faculty of Pharmacy, Aristotle University of Thessaloniki, 54124, Thessaloniki, Greece.
Christos MoutroupidisDepartment of Pharmaceutical Technology, Faculty of Pharmacy, Aristotle University of Thessaloniki, 54124, Thessaloniki, Greece.
Kevin M G TaylorDepartment of Pharmaceutics, UCL School of Pharmacy, 29-39 Brunswick Square, London, WC1 1AX, UK.
Kyriakos KachrimanisDepartment of Pharmaceutical Technology, Faculty of Pharmacy, Aristotle University of Thessaloniki, 54124, Thessaloniki, Greece.
Maria MalamatariDepartment of Pharmacy, School of Health Sciences, Frederick University, Nicosia, 1036, Cyprus.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pharmaceutical nanosuspensions, also called nanocrystals, are heterogeneous mainly aqueous dispersions of insoluble drug particles stabilised by surfactants and/or polymers. Nanosuspensions as liquid formulations suffer from instability. Solidification of nanosuspensions to solid dosage forms is a way to combine the advantages of nanocrystals with the advantages of the solid state. In this review, advances regarding stabilisation and production of nanosuspensions are briefly covered. Updates on the methods used to convert nanosuspensions to solid oral dosage forms (e.g., powder, granules, pellets, tablets, and films) are presented in depth. From these methods, spray drying and freeze drying are widely used. Granulation and hot-melt extrusion allow straightforward downstream processing, while printing exhibits the potential for dose personalisation. Focus is given on novel formulations (e.g., nano-cocrystals, nanocrystalline solid dispersions) which could further enhance the dissolution and bioavailability of poorly soluble drugs.

Indexed as

Drug CompoundingNanoparticlesSuspensionsAdministration, OralChemistry, PharmaceuticalDosage FormsHumansSolubilityDosage FormsSuspensions

Identifiers

PMID39752860
PMCPMC11698592

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.